GleamWall
中文EN

GPCR Structure Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1888886 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-39.5%
TTM EPS YoY-6.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.5%
ROA-27.1%
ROIC (approx.)-32.3%
Asset turnover—

Leverage & solvency

Liabilities / assets8.4%
Debt / equity0.00x
Current ratio11.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$225.25M$108.81M
SG&A expense$61.55M$49.41M
Operating income-$176.56M-$158.23M
Pretax income-$140.69M-$122.22M
Income tax$515,000$310,000
Net income-$141.20M-$122.53M
EBITDA-$175.23M-$157.24M
EPS (basic)-0.80-0.78
EPS (diluted)-0.80-0.78
Weighted avg. shares (diluted)177.60M157.92M
Balance sheet
Cash & equivalents$799.62M$169.51M
Short-term investments$646.57M$714.01M
Current assets$1.57B$891.21M
PP&E, net$6.65M$3.48M
Total assets$1.58B$903.33M
Current liabilities$63.28M$36.02M
Total liabilities$67.54M$38.49M
Shareholders' equity$1.52B$864.84M
Shares outstanding212.51M171.86M
Cash flow statement
Operating cash flow-$222.20M-$116.64M
Capital expenditure$3.61M$1.29M
Free cash flow-$225.81M-$117.93M
Investing cash flow$89.80M-$358.91M
Financing cash flow$762.52M$515.26M
Depreciation & amortization$1.33M$992,000
Stock-based compensation$28.99M$18.79M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.